Basel-based venture capitalist firm BioMedPartners has closed its new venture capital fund BioMedInvest III at 100 million Swiss francs. The fund will help drive growth in the Swiss life science cluster by investing in private early-to-mid-stage companies.
Main investors in the BioMedInvest III healthcare venture capital fund are the European Investment Fund and the Berner Kantonalbank. According to Markus Hosang, General Partner at BioMedPartners, his company also succeeded in gaining the Basellandschaftliche Kantonalbank and several important individuals as new investors.
“We are proud of having established BioMedPartners as a leading venture group and early-stage life science investor in Europe over the last 15 years since its inception,” added Thomas Möller, General Partner at BioMedPartners. “The successful closing of our third equity venture fund is also a major milestone for the future growth of the Life Science Cluster in Switzerland.”
The Basel-based company will invest 100 million Swiss francs in 12 to 15 biopharmaceutical, medical device and diagnostics companies. It will also take an active role in these companies. BioMedPartners will provide its expertise and access to its network of industry experts and scientific leaders.
Focus on Swiss companies
The fund’s focus is on Swiss companies as well as those from neighbouring countries. For instance, its first three investments are: Allecra Therapeutics, a French antibiotics company based in the Basel area, Amal Therapeutics in Geneva, and the German biotech company Cardior Pharmaceuticals.